Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / Common Stock - $0.001 par value
-
Shares outstanding
-
127,940,509
-
Total 13F shares
-
35,038,930
-
Share change
-
+667,797
-
Total reported value
-
$571,924,873
-
Price per share
-
$16.32
-
Number of holders
-
51
-
Value change
-
-$4,872,187
-
Number of buys
-
30
-
Number of sells
-
22
Institutional Holders of Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) as of Q4 2021
As of 31 Dec 2021,
Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) was held by
51 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
35,038,930 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., HHLR ADVISORS, LTD., Miura Global Management, LLC, FIL Ltd, FMR LLC, BlackRock Inc., ORBIMED ADVISORS LLC, VANGUARD GROUP INC, PURA VIDA INVESTMENTS, LLC, and Octagon Capital Advisors LP.
This page lists
51
institutional shareholders reporting positions in this security
for the Q4 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.